|Bid||43.85 x 1100|
|Ask||43.90 x 1300|
|Day's Range||43.74 - 45.43|
|52 Week Range||20.10 - 300.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||98.00|
CALGARY, May 24, 2019 /CNW/ - Inner Spirit Holdings Ltd. ("Inner Spirit" or the "Company") (CSE:ISH.CN - News) today announced it has closed its previously announced offering (the "Offering") of secured convertible debenture units of the Company (the "Debenture Units") for aggregate gross proceeds of $9,270,000. The Offering was made through a syndicate of agents, co-led by Acumen Capital Finance Partners Limited, as sole bookrunner, and Canaccord Genuity Corp. "The Company is very pleased to complete this $9.3 million financing.
Shareholder votes scheduled for June 19 will decide the fate of an agreement to combine the largest cannabis players in Canada and the U.S., Canopy Growth and Acreage Holdings.
Tilray, Inc. (“Tilray” or “the Company”) (TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today announced that its wholly-owned subsidiary Tilray Portugal Unipessoal Lda.
How Do Cannabis Stocks' Valuations Stack Up in May?(Continued from Prior Part)TilrayTilray (TLRY) has exhibited extended weakness for the most part of this year, and the trend did not reverse even after the company reported its earnings. Needless to
How Do Cannabis Stocks' Valuations Stack Up in May?Earnings releasesCannabis companies such as Tilray (TLRY), Aurora Cannabis (ACB), and CannTrust (CTST) reported their earnings last week, which gave us fresh insight into the cannabis sector. While
Aphria Stock Rises on Cultivation License in Germany(Continued from Prior Part)Cannabis stocks gainToday, the cannabis sector was making positive moves after last week was fraught with pessimism due to trade tensions. HEXO (HEXO) was up 1.3% while
Novartis CEO Vas Narasimhan says cannabis is not a priority for the Swiss drugmaker despite its partnership with Canadian marijuana giant Tilray. Novartis NOVN-CH CEO Vas Narasimhan said Tuesday that cannabis is not a priority for the Swiss drugmaker despite its partnership with Canadian marijuana giant Tilray TLRY .
Based on its peers' results, Canopy Growth could be in for a pretty good quarter.
Cannabis Stocks Fell despite Biden's Support of Legalization(Continued from Prior Part)TLRY edges lowerTilray (TLRY) continued to move lower in the first half of today with the stock declining by nearly 1.8% around noon. The company has been in the
Cowen and Co. report notes that recreational use of the drug Canada is surging, and the rise of pot is a headwind to beer sales.
Tilray CEO Says Some Cannabis Companies Misled Investors(Continued from Prior Part)Tilray CEO’s salaryLast week, Bloomberg reported a list of the highest paid CEOs in 2018. Interestingly, Tilray’s (TLRY) CEO, Brendan Kennedy, was the second
Cannabis Stocks Experienced Extended Weakness Last Week(Continued from Prior Part)Tilray fell last weekTilray (TLRY) reported its earnings on May 14. The company reported revenues of $23 million—better than the expectation of $20.2 million. The
Tilray CEO Says Some Cannabis Companies Misled InvestorsTilray’s CEO in focusLast week, Tilray’s (TLRY) CEO claimed that some cannabis companies have misled investors by inflating their capacity metrics, which could have skewed valuations
Pot stocks were more concerned with supporting inflated valuations than meeting grow expectations, according to this prominent cannabis CEO.
The "Cannabis Craze" had everyone and their brother buying up marijuana stocks. These cannabis stocks didn't have enough free-floating shares to cover the massive amount of buy interest leading them to skyrocketed at the end of 2018 far above their fair value.
Tilray: Big Price Cut after Its Q1 Earnings(Continued from Prior Part)Tilray’s valuationTilray (TLRY) stock has been trading at a premium valuation compared to its peers, which doesn’t seem justified. Tilray’s decline seemed imminent—like